Sugi Predict

Sugi Predict / Compounds / SCHEMBL29397883

SCHEMBL29397883

SCHEMBL29397883

O=C1CN(C(=O)c2cc(-c3cc(F)cc(Cl)c3)n(-c3ccc(F)c(Cl)c3)n2)CN1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ MALT1 Q9UDY8 2/20 0.44
▸ RPA1 P27694 4/20 0.40
▸ ATM Q13315 1/20 0.40
▸ PPP1CA P62136 1/20 0.39
▸ CHRNA7 P36544 2/20 0.39
▸ PTGS2 P35354 5/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1526038 1.00 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1765424 0.93 MEN1 (0.44) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1764920 0.92 MEN1 (0.43) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1765015 0.91 MEN1 (0.50) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1765282 0.90 MEN1 (0.42) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1764969 0.90 PTGS2 (0.48) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1765351 0.90 PPP1CA (0.46) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1765442 0.90 KDM1A (0.45) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL1764936 0.90 RPA1 (0.44) MEN1KMT2AMAPTSMN1; SMN2NPSR1
SCHEMBL15004283 0.89 MEN1 (0.44) MEN1KMT2AMAPTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080069-A Phospholipid compounds and uses thereof — 2026-05-26 — — CN disclosed
US-12636279-B2 Choline salt forms of an HIV capsid inhibitor GILEAD SCIENCES, INC. (US) 2026-05-26 — — US disclosed
CN-122055369-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 — — CN disclosed
CN-122055373-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 — — CN disclosed
CN-122036801-A Crystalline forms of tenofovir alafenamide 吉利德科学公司 2026-05-15 — — CN disclosed
US-20260132139-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-14 — — US disclosed
CN-122005785-A Method for identifying HIV patients susceptible to therapy with GP 120V 3 glycan-directed antibodies 吉利德科学公司 2026-05-12 — — CN disclosed
WO-2026090160-A2 CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE GILEAD SCIENCES, INC. (US) 2026-04-30 — — WO disclosed
US-20260109746-A1 CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
EP-4720056-A1 SOLID FORMS OF COMPOUNDS USEFUL IN THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2026-04-08 — — EP disclosed
US-20220081455-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2022-03-17 — — US disclosed
US-20220073473-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2022-03-10 — — US disclosed
US-11267799-B2 Solid forms of an HIV capsid inhibitor GILEAD SCIENCES, INC. (US) 2022-03-08 — — US disclosed
US-11267801-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2022-03-08 — — US disclosed
US-11266638-B2 Choline salt forms of an HIV capsid inhibitor GILEAD SCIENCES, INC. (US) 2022-03-08 — — US disclosed
WO-2022046631-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2022-03-03 — — WO disclosed
EP-3960740-A1 CRYSTALLINE FORMS OF ETHYL ((S)-((((2R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-FLUORO-2,5-DIHYDROFURAN-2-YL)OXY)METHYL)(PHENOXY)PHOSPHORYL)-L-ALANINATE (GS-9131) VANILLATE FOR TREATING VIRAL INFECTIONS Gilead Sciences, Inc. (US) 2022-03-02 — — EP disclosed
EP-3960735-A1 QUINAZOLINE DERIVATIVES USED TO TREAT HIV Gilead Sciences, Inc. (US) 2022-03-02 — — EP disclosed
EP-3955921-A1 2-IMINO-5-OXO-IMIDAZOLIDINE INHIBITORS OF HIV PROTEASE GILEAD SCIENCES, INC. (US) 2022-02-23 — — EP disclosed
US-20220049021-A1 FLT3L-Fc FUSION PROTEINS AND METHODS OF USE GILEAD SCIENCES, INC. 2022-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073473-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS TLR8, TLR3, TLR6 MEN1 4813/4885KMT2A 2849/4885MAPT 3599/4885
US-11267801-B2 Therapeutic compounds NPC1, CCR5, FURIN MEN1 1720/4885KMT2A 3635/4885MAPT 300/4885
US-12636279-B2 Choline salt forms of an HIV capsid inhibitor CHKA, SLC5A7, SLC44A1 MEN1 3926/4885KMT2A 346/4885MAPT 158/4885
US-20220081455-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF PHOSPHO1, SGMS2, SGMS1 MEN1 578/4885KMT2A 3795/4885MAPT 4064/4885
US-11266638-B2 Choline salt forms of an HIV capsid inhibitor CHKA, SLC44A1, SLC5A7 MEN1 4174/4885KMT2A 406/4885MAPT 150/4885
US-20260132139-A1 HIV INHIBITOR COMPOUNDS SLC11A2, SLC6A15, NHERF1 MEN1 1958/4885KMT2A 2228/4885MAPT 479/4885
US-20260109746-A1 CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE IL15, IL15RA, CD4 MEN1 973/4885KMT2A 3253/4885MAPT 1544/4885
US-11267799-B2 Solid forms of an HIV capsid inhibitor ZC3HAV1, ZC3HAV1L, PRNP MEN1 4795/4885KMT2A 879/4885MAPT 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.